Alzheimer’s disease (AD) is the progressive brain disorder which degenerates brain cells connection and causes memory loss. Although AD is irreversible, it is not impossible to arrest or slow down the progression of the disease. However, this would only be possible if the disease is diagnosed at an early stage, and early diagnosis requires clear understanding of the pathogenesis at molecular level. Overactivity of GSK-3β and p53 accounts for tau hyperphosphorylation and the formation of amyloid-β plaques.
Objective:
Here, we explored GSK-3β and p53 as blood-based biomarkers for early detection of AD.
Methods:
The levels of GSK-3β, p53, and their phosphorylated states were measured using surface plasmon resonance and verified using western blot in serum from AD, mild cognitive impairment (MCI), and geriatric-control (GC) subjects. The neurotoxic SH-SY5Y cell line was treated with antioxidant Emblica Officinalis (EO) for rescue effect.
Results:
GSK-3β, p53, and their phosphorylated states were significantly over expressed (p > 0.001) in AD and MCI compared to GC and can differentiate AD and MCI from GC. The expression level of GSK-3β and p53 proteins were found to be downregulated in a dose-dependent manner after the treatment with EO in amyloid-b-induced neurotoxic cells.
Conclusion:
These proteins can serve as potential blood markers for the diagnosis of AD and EO can suppress their level. This work has translational value and clinical utility in the future.
DobleBW, WoodgettJR (2007) Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs185, 73–84.
2.
CaiZ, ZhaoY, ZhaoB (2012) Roles of glycogen synthase kinase 3 in Alzheimer’s disease. Curr Alzheimer Res9, 864–879.
3.
HolsingerRMD, McLeanCA, BeyreutherK, MastersCL, EvinG (2002) Increased expression of the amyloid precursor β-secretase in Alzheimer’s disease. Ann Neurol51, 783–786.
4.
DonmezG, WangD, CohenDE, GuarenteL (2010) SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell142, 320–332.
5.
KumarR, ChatterjeeP, SharmaPK, SinghAK, GuptaA, GillK, TripathiM, DeyAB, DeyS (2013) Sirtuin1: A promising serum protein marker for early detection of Alzheimer’s disease. PLoS One8, e61560.
6.
HaassC, SelkoeDJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol8, 101–112.
7.
DajaniR, FraserE, RoeSM, YoungN, GoodV, DaleTC, PearlLH (2001) Crystal structure of glycogen synthase kinase 3β: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell105, 721–732.
8.
LeeVMY, GoedertM, TrojanowskiJQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci24, 1121–1159.
9.
HoshiM, TakashimaA, NoguchiK, MurayamaM, SatoM, KondoS, SaitohY, IshiguroK, HoshinoT, ImahoriK (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3β in the brain. U S A93, 2719–2723.
10.
FarmerKM, GhagG, PuangmalaiN, MontalbanoM, BhattN, KayedR (2020) P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease. Acta Neuropathol Commun8, 132.
HooperC, MeimaridouE, TavassoliM, MelinoG, LovestoneS, KillickR (2007) p53 is upregulated in Alzheimer’s disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett418, 34–37.
13.
EunB, ChoB, MoonY, KimSY, KimK, KimH, SunW (2010) Induction of neuronal apoptosis by expression of Hes6 via a p53-dependent pathway. Brain Res1313, 1–8.
14.
ChangJR, GhafouriM, MukerjeeR, BagashevA, ChabrashviliT, SawayaBE (2012) Role of p53 in neurodegenerative diseases. Neurodegener Dis9, 68–80.
15.
Bech-OtschirD, KraftR, HuangX, HenkleinP, KapelariB, PollmannC, DubielW (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J20, 1630–1639.
16.
LavinMF, GuevenN (2006) The complexity of p53 stabilization and activation. Cell Death Differ13, 941–950.
17.
OlmosY, Sánchez-GómezFJ, WildB, García-QuintansN, CabezudoS, LamasS, MonsalveM (2013) SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex. Antioxidants Redox Signal19, 1507–1521.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group* under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology34, 939–944.
20.
ShekharS, YadavY, SinghAP, PradhanR, DesaiGR, DeyAB, DeyS (2018) Neuroprotection by ethanolic extract of Syzygium aromaticum in Alzheimer’s disease-like pathology via maintaining oxidative balance through SIRT1 pathway. Exp Gerontol110, 277–283.
21.
LeroyK, BrionJP (1999) Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J Chem Neuroanat16, 279–293.
22.
BhatR V., ShanleyJ, CorrellMP, FilesWE, KeithRA, ScottCW, LeeCM (2000) Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A97, 11074–11079.
23.
MaylorEA, ReimersS, ChoiJ, CollierML, PetersM, SilvermanI (2007) Gender and sexual orientation differences in cognition across adulthood: Age is kinder to women than to men regardless of sexual orientation. Arch Sex Behav36, 235–249.
24.
KitamuraY, ShimohamaS, KamoshimaW, MatsuokaY, NomuraY, TaniguchiT (1997) Changes of p53 in the brains of patients with Alzheimer’s disease. Biochem Biophys Res Commun232, 418–421.
25.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 29–44.
26.
GilmanCP, ChanSL, GuoZ, ZhuX, GreigN, MattsonMP (2003) p53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults. Neuromolecular Med3, 159–172.
27.
WatcharasitP, BijurGN, SongL, ZhuJ, ChenX, JopeRS (2003) Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem278, 48872–48879.
28.
ProctorCJ, GrayDA (2010) GSK3 and p53 - Is there a link to Alzheimer’s disease?Mol Neurodegener5, 7.
29.
KumarR, NigamL, SinghAP, SinghK, SubbaraoN, DeyS (2017) Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in a cellular model of Alzheimer’s disease. Eur J Med Chem127, 909–916.
30.
KimTS, PaeCU, YoonSJ, JangWY, LeeNJ, KimJJ, LeeSJ, LeeC, PaikIH, LeeCU (2006) Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatr Psychiatry21, 344–348.
31.
LakhotiaSC (2013) Neurodegeneration disorders need holistic care and treatment - Can Ayurveda meet the challenge?Ann Neurosci20, 1–2.
32.
SinghN, BhallaM, de JagerP, GilcaM (2011) An overview on Ashwagandha: A Rasayana (Rejuvenator) of Ayurveda. African J Tradit Complement Altern Med8, 208–213.
SinghSK, SrivastavS, CastellaniRJ, Plascencia-VillaG, PerryG (2019) Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics16, 666–674.
35.
PozharitskayaON, IvanovaSA, ShikovAN, MakarovVG (2007) Separation and evaluation of the free radical-scavenging activity of phenol components of Emblica officinalis extract by using an HPTLC-DPPH⋅ method. J Sep Sci30, 1250–1254.
36.
LuoW, ZhaoM, YangB, ShenG, RaoG (2009) Identification of bioactive compounds in Phyllanthus Emblica L. fruit and their free radical scavenging activities. Food Chem114, 499–504.
37.
EmamghoreishiM, FarrokhiMR, AmiriA, KeshavarzM (2019) The neuroprotective mechanism of cinnamaldehyde against amyloid-β in neuronal SHSY5Y cell line: The role of N-methyl-D-aspartate, ryanodine, and adenosine receptors and glycogen synthase kinase-3β. Avicenna J Phytomed9, 271–280.
38.
UddinMS, MamunA Al, HossainMS, AkterF, IqbalMA, AsaduzzamanM (2016) Exploring the effect of Phyllanthus Emblica L. on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: Promising natural gift for the mitigation of Alzheimer’s disease. Ann Neurosci23, 218–229.
